Li‐Min Lao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Li‐Min Lao has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Changzheng Huang
Department of Dermatology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
1 shared publication - Xiao-Yong Man
Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication Xiu‐Yun Xuan
Department of Dermatology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei China
1 shared publication- Yanhong Sun
Department of Dermatology, Second Affiliated Hospital of Zhejiang University, Hangzhou, China
1 shared publication - Ying Shen
Department of Dermatology The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou Zhejiang China
1 shared publication
Latest Publications
- 10 October 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (11) , e15848
Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: A retrospective case series
Rosacea is a chronic inflammatory skin disease characterized by facial erythema, papules, pustules, telangiectasia, and flushing. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway appears to play a role in the pathogenesis of rosacea. Our study preliminarily explored the efficacy of JAK inhibitor tofacitinib in the treatment of rosacea. We retrospectively reviewed the cases of 21 patients with rosacea who were treated with oral tofacitinib. Patients received oral tofacitinib 5 mg as either monotherapy or adjunctive therapy. We have observed that 15 out of 21 patients (71.4%) patients experienced significant regression of erythema on the face (IGA ≤ 1), and a mean change of -2.24 in the Investigator's Global Assessment (IGA) score was significant improvement from baseline. Treatment with oral tofacitinib might be a potentially effective treatment to ameliorate the symptoms of rosacea.
- 10 October 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (11) , e15848
Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: A retrospective case series
Rosacea is a chronic inflammatory skin disease characterized by facial erythema, papules, pustules, telangiectasia, and flushing. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway appears to play a role in the pathogenesis of rosacea. Our study preliminarily explored the efficacy of JAK inhibitor tofacitinib in the treatment of rosacea. We retrospectively reviewed the cases of 21 patients with rosacea who were treated with oral tofacitinib. Patients received oral tofacitinib 5 mg as either monotherapy or adjunctive therapy. We have observed that 15 out of 21 patients (71.4%) patients experienced significant regression of erythema on the face (IGA ≤ 1), and a mean change of -2.24 in the Investigator's Global Assessment (IGA) score was significant improvement from baseline. Treatment with oral tofacitinib might be a potentially effective treatment to ameliorate the symptoms of rosacea.